MeiraGTx Holdings plc Finance Lease, Liability, to be Paid, Year Five
MeiraGTx Holdings plc (MGTX) had Finance Lease, Liability, to be Paid, Year Five of $0 as of 2022-09-30, per its 10-Q filed 2022-11-10.
Discontinued › Notes › Finance Lease, Liability, to be Paid, Fiscal Year Maturity
us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive · last filed 2022-11-10
- 2022-09-30: Finance Lease, Liability, to be Paid, Year Five $0.00.
- 2022-06-30: Finance Lease, Liability, to be Paid, Year Five $0.00.
- 2022-03-31: Finance Lease, Liability, to be Paid, Year Five $0.00.
- 2019-09-30: Finance Lease, Liability, to be Paid, Year Five $0.00.
| Period end | Finance Lease, Liability, to be Paid, Year Five |
|---|---|
| 2022-09-30 | $0.00 10-Q · filed 2022-11-10 |
| 2022-06-30 | $0.00 10-Q · filed 2022-08-11 |
| 2022-03-31 | $0.00 10-Q · filed 2022-05-12 |
| 2019-09-30 | $0.00 10-Q · filed 2019-11-07 |
| 2019-06-30 | $0.00 10-Q · filed 2019-08-07 |
| 2019-03-31 | $0.00 10-Q · filed 2019-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |